Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
zifibancimig
- Development stage
- Phase 2
- Lead developer
- Roche
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Administration
- Intravitreal, Implant, Ophthalmic
01
Overview
Zifibancimig is an investigational bispecific monoclonal antibody designed for the treatment of neovascular (wet) age-related macular degeneration (nAMD). It targets and inhibits both angiopoietin-2 (Ang-2) and vascular endothelial growth factor A (VEGF-A), two key mediators involved in abnormal blood vessel growth, vascular leakage, and inflammation in the retina. By simultaneously blocking these pathways, zifibancimig aims to stabilize retinal vessels, reduce leakage and inflammation, inhibit neovascularization, and potentially provide a more durable therapeutic effect compared to single-target agents. The drug is administered via intravitreal injection or through a Port Delivery implant system for sustained intraocular release. Zifibancimig is currently being evaluated in Phase 1/2 clinical trials for safety, tolerability, pharmacokinetics, and efficacy in patients with nAMD[1][2][3][5][6].
02
Targets
ANGPT2 (Angiopoietin-2)VEGFA (Vascular endothelial growth factor A)VEGFR2 (Vascular endothelial growth factor receptor 2)
Beyond the preview
Go deeper on zifibancimig.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on zifibancimig.